Global life sciences executive search and interim management specialist RSA has placed Jack Talley as president and chief executive of Actinium Pharmaceuticals.

Actinium tasked RSA with finding a seasoned executive to strengthen its senior management team, as the company prepares to raise additional capital and list on the public stock markets later this year.

Private biopharmaceutical company Actinium develops innovative targeted radio-immunotherapeutics to treat various cancers. With more than 30 years of experience in marketing, drug development and regulatory matters, Talley was found to be the right candidate at this critical moment in the firm’s history.

Shawn O’Connor, president of RSA Americas, says “We are delighted to conclude our search with the placement of such an exceptional candidate. Previously the CEO of EpiCept Corporation, Jack has immense experience in the industry and we believe he is well positioned to succeed in his new role.”